SEC Filings

Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT^® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

Filing date	Form	Description	View
Nov 01, 2022	8-K	Report of unscheduled material events or corporate event	View HTML 0001104659-22-113205.pdf 0001104659-22-113205.rtf 0001104659-22-113205.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Nov 01, 2022	10-Q	Quarterly report which provides a continuing view of a company's financial position	View HTML 0001558370-22-015808.pdf 0001558370-22-015808.rtf 0001558370-22-015808.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Oct 05, 2022	4	Statement of changes in beneficial ownership of securities	View HTML 0001415889-22-010366.pdf 0001415889-22-010366.rtf 0001415889-22-010366.xls
Sep 23, 2022	8-K	Report of unscheduled material events or corporate event	View HTML 0001104659-22-102734.pdf 0001104659-22-102734.rtf 0001104659-22-102734.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Sep 07, 2022	8-K	Report of unscheduled material events or corporate event	View HTML 0001104659-22-098213.pdf 0001104659-22-098213.rtf 0001104659-22-098213.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Aug 26, 2022	4	Statement of changes in beneficial ownership of securities	View HTML 0001415889-22-009131.pdf 0001415889-22-009131.rtf 0001415889-22-009131.xls
Aug 23, 2022	4	Statement of changes in beneficial ownership of securities	View HTML 0001415889-22-008977.pdf 0001415889-22-008977.rtf 0001415889-22-008977.xls
Aug 18, 2022	4	Statement of changes in beneficial ownership of securities	View HTML 0001415889-22-008861.pdf 0001415889-22-008861.rtf 0001415889-22-008861.xls
Aug 17, 2022	8-K	Report of unscheduled material events or corporate event	View HTML 0001104659-22-092002.pdf 0001104659-22-092002.rtf 0001104659-22-092002.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Aug 10, 2022	4	Statement of changes in beneficial ownership of securities	View HTML 0001415889-22-008476.pdf 0001415889-22-008476.rtf 0001415889-22-008476.xls

Investors & Media

Transformative science, targeted medicines

SEC Filings

Pagination